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ABSTRACT 
 
Dietary supplementation with inorganic nitrate (NO3-) has been reported to improve 
cardiovascular health indices in healthy adults.  Cigarette smoking increases circulating 
thiocyanate (SCN-), which has been suggested to competitively inhibit salivary nitrate (NO3-) 
uptake, a rate-limiting step in dietary NO3- metabolism.  Therefore, this study tested the 
hypothesis that dietary NO3- supplementation would be less effective at increasing the 
circulating plasma nitrite concnetration ([NO2-]) and lowering blood pressure in smokers (S) 
compared to non-smokers (NS).  Nine  healthy smokers and eight healthy non-smoking 
controls reported to the laboratory at baseline (CON) and following six day supplementation 
periods with 140 ml∙day-1 NO3--rich (8.4 mmol NO3-∙day-1; NIT) and NO3--depleted (0.08 
mmol NO3-∙day-1; PLA) beetroot juice in a cross-over experiment.  Plasma and salivary 
[SCN-] were elevated in smokers compared to non-smokers in all experimental conditions 
(P<0.05).  Plasma and salivary [NO3-] and nitrite ([NO2-]) were elevated in the NIT condition 
compared to CON and PLA conditions in smokers and non-smokers (P<0.05).  However, the 
change in salivary [NO3-] (S: 3.5 ± 2.1 vs. NS: 7.5 ± 4.4 mM), plasma [NO3-] (S: 484 ± 198 
vs. NS: 802 ± 199 μM) and plasma [NO2-] (S: 218 ± 128 vs. NS: 559 ± 419 nM) between the 
CON and NIT conditions was lower in the smokers compared to the non-smokers (P<0.05).  
Salivary [NO2-] increased above CON to a similar extent with NIT in smokers and non-
smokers (P>0.05).  Systolic blood pressure was lowered compared to PLA with NIT in non-
smokers (P<0.05), but not smokers (P>0.05).  These findings suggest that dietary NO3- 
metabolism is compromised in smokers leading to an attenuated blood pressure reduction 
compared to non-smokers after NO3- supplementation.  These observations may provide 
novel insights into the cardiovascular risks associated with cigarette smoking and suggest that 
this population may be less likely to benefit from improved cardiovascular health if they 
increase dietary NO3- intake.       
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1. INTRODUCTION 
 
Cardiovascular disease is the leading cause of mortality in developed countries and costs the 
global economy approximately US$3.7 trillion per annum [1].  As such, interventions that 
can lower cardiovascular disease morbidity will be of epidemiological and economic 
importance.  It has long been appreciated that a diet rich in fruit and vegetables lowers the 
risk of developing cardiovascular diseases and the incidence of adverse cardiovascular events 
such as stroke, heart failure and coronary heart disease [2,3].  Consequently, there are 
numerous government-driven initiatives to increase fruit and vegetable consumption 
including the Dietary Approaches to Stop Hypertension (DASH) diet in the United States of 
America [4], the 5-A-Day diet in the United Kingdom [5] and variations of this latter diet in 
countries within the European Union [6].   
 
It has been suggested that the cardio-protective effects of diets rich in fruit and vegetables 
might be linked to their high inorganic nitrate (NO3-) content [7-9].  Vegetable consumption 
accounts for 60-80% of dietary NO3- intake [10] with leafy-green vegetables (e.g., spinach 
and lettuce varieties) and beetroot being particularly rich in NO3- [7].  It has been reported 
that consuming 5 portions of NO3--rich vegetables for 7 days, which provided a daily NO3- 
intake of ~ 317 mg (5.1 mmol), lowered systolic blood pressure, whereas a control diet where 
participants avoided NO3--rich vegetables, resulting in a daily NO3- intake of ~ 8 mg (0.1 
mmol), did not [9].  Increased dietary NO3- intake in the form of NO3--rich beetroot [11-13] 
or spinach [14,15] supplementation alone has also been shown to lower resting blood 
pressure.  These findings are consistent with the emerging body of evidence to support 
improved vascular health following dietary NO3- supplementation (4-16 mmol·day-1) in 
younger [11-13] and older [16,17] normotensive adults, and in individuals with hypertension 
[18], peripheral artery disease [19] and heart failure [20].  Therefore, enriching the diet with 
NO3-, at a dose that can be readily achieved by a diet high in vegetables [4,7,9], might 
represent a practical and cost-effective intervention to lower cardiovascular disease morbidity 
and mortality.  
 
After oral ingestion, approximately 25% of NO3- passes into the entero-salivary circulation 
[21].  Subsequently, NO3- is concentrated and delivered within saliva to the oral cavity where 
facultative microflora reduce NO3- to nitrite (NO2-) [21-25].  NO2--rich saliva is then ingested 
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and NO2- is further reduced to nitric oxide (NO) and other reactive nitrogen intermediates in 
the acidic environment of the stomach [26-27].  It is also clear that a portion (in the nM 
range) of the ingested NO2- passes into the systemic circulation [24] where it can impact 
vascular function directly [28,29] or through its subsequent reduction to NO via a number of 
NO2- reductases [30].  Although mammalian tissues have the capacity to directly metabolise 
NO3- [34], the entero-salivary delivery of NO3- to the oral cavity and its subsequent reduction 
to NO2- by lingual anaerobes, are key rate limiting steps of NO3- metabolism in mammals 
[35].  There is evidence to suggest that the uptake of NO3- into the salivary circulation occurs 
in competition with perchlorate, thiocyanate (SCN-) and iodide [36].  Therefore, increased 
exposure to perchlorate, SCN- or iodide may interfere with dietary NO3- metabolism and 
might subsequently blunt the improvements in vascular health that have typically been 
observed after increased dietary NO3- intake.       
 
Cigarette smoking is a major risk factor for cardiovascular disease morbidity and mortality 
[37-39], and a leading cause of preventable death worldwide [38,40].  In spite of global 
government initiatives to facilitate smoking cessation, there are still an estimated 1 billion 
smokers worldwide [41].  Cigarette smoke contains over 7000 noxious chemicals, including 
cyanide [38].  Following consumption, cyanide is rapidly detoxified to thiocyanate (SCN-) 
via transsulfuration reactions catalysed by the enzymes, thiosulfate sulfotransferase 
(rhodanase) and 3-mercaptopyruvate sulfurtransferase [42].  Consequently, cigarette smokers 
have elevated plasma and salivary [SCN-] compared to non-smoking controls [e.g., 43].  
Importantly, and consistent with a competitive inhibition of salivary NO3- uptake by SCN- 
[36], it has been reported that salivary [NO3-] is lower in cigarette smokers after NO3- 
ingestion, compared to non-smoking controls [44,45].  However, in spite of a lower salivary 
[NO3-] after NO3- ingestion in smokers, the increase in salivary [NO2-] was not different 
between the smokers and non-smokers [44].  It is therefore unclear whether cigarette smoking 
interferes with the increases in plasma [NO2-] and the associated reduction of blood pressure 
that has been observed following dietary NO3- ingestion in non-smokers [12,13,31,33].  
Further research is required to elucidate the effects of cigarette smoking on dietary NO3- 
metabolism and its implications for vascular health.  If dietary NO3- metabolism is indeed 
perturbed by cigarette smoking, this may provide new insights into the mechanisms by which 
cigarette smoking increases cardiovascular disease morbidity.   
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The purpose of this study was to assess the effects of six days dietary NO3- supplementation 
on plasma and salivary [NO3-], [NO2-] and [SCN-] and resting blood pressure in smokers and 
non-smoking controls.  It was hypothesized that the increases in salivary [NO3-], plasma 
[NO3-] and plasma [NO2-], but not salivary [NO2-], after dietary NO3- supplementation would 
be attenuated in cigarette smokers compared to non-smoking controls.  It was also 
hypothesised that dietary NO3- supplementation would lower blood pressure in non-smokers, 
but not in smokers.    
 
2. MATERIALS AND METHODS 
 
2.1 Subjects  
We recruited nine cigarette smokers (5 males, mean ± SD, age 24 ± 7 yr, body mass index 23 
± 2 kg·m2; smoking history 7 ± 6 pack years) and eight age- and BMI-matched non-smoking 
controls (4 males, mean ± SD, age 24 ± 5 yr, body mass index 23 ± 4 kg·m2) from the 
University staff and student communities to participate in this study.  Both the smokers 
[forced vital capacity (FVC) 4.68 ± 1.02 L; forced expiratory volume in 1-s (FEV1) 4.26 ± 
0.99 L; FEV1/ FVC 91 ± 6 %] and non-smokers (FVC, 4.17 ± 0.76 L; FEV1, 3.64 ± 0.57 L; 
FEV1/ FVC 88 ± 5 %] exhibited normal resting pulmonary function and had a similar level of 
habitual physical activity, as assessed by the Baecke et al. [46] questionnaire (smokers, 7.2 ± 
1.7; non-smokers 7.2 ± 1.7), upon recruitment to the study.  All procedures employed in this 
study were approved by the Institutional Research Ethics Committee and subjects gave their 
written informed consent to participate prior to the commencement of the study, after the 
experimental procedures, associated risks, and potential benefits of participation had been 
explained.  Subjects were instructed to arrive at each laboratory testing session in a rested and 
fully hydrated state, at least 3 h postprandial.  Since the reduction of NO3- to NO2- in the oral 
cavity is compromised by antibacterial mouthwash [47], subjects were required to refrain 
from mouthwash use for the duration of the study.  Each subject was also asked to avoid 
consumption of nitrate-rich foods for the duration of the study, and from caffeine and alcohol 
ingestion 6 and 24 h before each test, respectively.  All subjects were instructed to maintain 
their habitual physical activity pattern for the duration of the study, and to avoid strenuous 
exercise in the 24 h preceding the testing sessions.   Smokers were asked to maintain their 
habitual smoking patterns for the duration of the study, but were required to abstain from 
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smoking for 3 h before each testing session.  All tests were performed at the same time of day 
(± 2 hours).    
 
2.2 Supplementation Procedures 
All subjects were required to report to the laboratory on three occasions over a 3-4 week 
period.  Subjects did not undergo dietary supplementation prior to their first visit to the 
laboratory (the control condition; CON).  Subjects were asked to record their food and 
beverage consumption on the day of the CON test and for the 5 days preceding this test and 
to replicate this prior to the subsequent trials.  After completing the CON trial, subjects were 
randomly assigned to receive six days of supplementation with either NO3--rich (NIT) or 
NO3--depleted beetroot juice as a placebo (PLA) as part of a double-blind, cross-over 
experimental design.  In the NIT and PLA conditions, subjects ingested 70 ml of concentrated 
beetroot juice containing 4.2 and 0.04 mmol NO3-, respectively, in the morning and evening 
over the first five days of supplementation.  Subjects ingested 140 ml of beetroot juice two 
hours before reporting to the laboratory on day six of NIT and PLA supplementation period.  
This was selected to coincide with the peak plasma [NO2-] attained following ingestion of 8.4 
mmol NO3- [13].  A 7-10 day washout separated the supplementation periods.               
 
2.3 Measurements 
2.3.1 Expired carbon monoxide and resting respiratory function  
Upon arrival at the laboratory the carbon monoxide (CO) content of subjects’ expired air was 
assessed in a standing position using a hand-held CO analyzer (Micro+ Smokerlyzer, Bedfont 
Scientific Ltd, Kent, UK).  For this assessment subjects were instructed to inhale to total lung 
capacity and then exhale slowly into the CO analyzer until they attained residual volume.  
Three manoeuvres were completed with the highest CO measurement used for analysis.  
Subjects then completed three FVC manoeuvres using a hand-held micro spirometer (Micro 
Plus, Micro Medical Ltd, Kent, UK) for the assessment of resting respiratory function (FVC, 
FEV1 and FEV1/ FVC).  For this assessment subjects were instructed to inhale to the total 
lung capacity and then exhale as quickly and forcefully as possible into the micro spirometer 
until they attained residual volume.  The data from the manoeuvre that produced the highest 
FVC were used for analysis.  Subjects were fitted with a nose clip during all these 
measurements to prevent the expiration of air through the nasal passage.   
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2.3.2 Blood Pressure 
Subjects were required to rest supine for 10 min in an isolated room. Thereafter, blood 
pressure of the brachial artery was measured whilst the subject was supine using an 
automated sphygmomanometer (Dinamap Pro, GE Medical Systems, Tampa, USA).  Five 
measurements were taken and the mean of the measurements 2-5 was used for analysis. 
 
2.3.3 Blood and saliva collection 
Venous blood samples were drawn into 6 mL lithium-heparin tubes (Sarstedt, Leicester, UK).   
Samples were centrifuged at 4,000 rpm and 4°C for 10 min, within 1 min of collection.  
Plasma was subsequently extracted and immediately frozen at -80°C for later analysis of 
[NO2-], [NO3-] and [SCN-].  Unstimulated saliva samples (~ 3 mL) were collected into 30 mL 
universal containers and 1 mL aliquots were frozen at -80°C for later analysis of [NO2-], 
[NO3-] and [SCN-].   
 
2.4 Data analysis procedures 
2.4.1 [NO3-] and [NO2-] determination 
All glassware, utensils, and surfaces were rinsed with deionized water to remove residual NO 
prior to [NO2-] and [NO3-] analysis.  Plasma samples were deproteinized using zinc 
sulfate/sodium hydroxide precipitation prior to determination of [NO3-]. Firstly, 500 μL of 
0.18 N NaOH was added to 100 µL of sample followed by 5 min incubation at room 
temperature.  Subsequently, samples were treated with 300 μL aqueous ZnSO4 (5% w/v) and 
vortexed for 30 seconds before undergoing an additional 10 min incubation period at room 
temperature. Samples were then centrifuged at 4,000 rpm for 5 min, and the supernatant was 
removed for subsequent analysis.  The [NO3-] of the deproteinized plasma sample was 
determined by its reduction to NO in the presence of 0.8 % (w/v) VCl3 in 1 M HCl within an 
air-tight purging vessel.  Plasma samples were introduced to the vessel via 100 μL injections 
into the septum at the top of the vessel.  The spectral emission of electronically excited 
nitrogen dioxide, derived from the reaction of NO with ozone, was detected by a 
thermoelectrically cooled, red-sensitive photomultiplier tube housed in a Sievers gas-phase 
chemiluminescence nitric oxide analyzer (Sievers NOA 280i. Analytix Ltd, Durham, UK). 
The [NO3-] was determined by plotting signal (mV) area against a calibration plot of sodium 
nitrate standards.  The [NO2-] of the undiluted (non-deproteinized) plasma was determined by 
its reduction to NO in the presence of glacial acetic acid and aqueous NaI (4% w/v), and 
calibrated using sodium nitrite standards.  After thawing at room temperature, saliva samples 
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were centrifuged for 10 min at 14000 rpm and the supernatant was removed for subsequent 
analysis.  The supernatant was diluted 100 fold with deionized water and [NO3-] and [NO2-] 
were determined from 50 μL injections using the same reagents describe above for the 
plasma analyses. 
 
2.4.2 [SCN-] determination 
Plasma and salivary [SCN-] were measured in duplicate using the procedures described by 
Tsuge et al. [43].  Briefly, 300 μL of plasma was treated with 200 μL of trichloroacetic acid   
(25% w/v) and centrifuged for 10 min at 14000 rpm.  The supernatant was then removed for 
subsequent analysis. 50 μL of sample, 15 μL x 1 M of ice-cold potassium hydrogen 
phosphate solution (pH 5.5), 5 μL of 5M NaOH solution, and 10 μL of 6.25mg/ml 
chloramine T solution were added to a 96-well microtiter plate (Sterilin Ltd., Caerphilly, UK) 
and incubated on ice for 2 min.  Subsequently, 120 μL of cyanoline blue solution (0.27 % 
w/v) was added to the microtiter plate and the plate was incubated for 20 min at room 
temperature.  Following incubation, sample absorbance was measured at 620 nm using a 
microplate reader (EnSpire 2300, Perkin Elmer, Hamburg, Germany).  Thawed saliva 
samples were centrifuged for 10 min at 14000 rpm and the supernatant was removed for 
subsequent analysis.  Samples were diluted 25 fold, and 40 μL of the diluted sample was 
added to a 96-well microtiter plate in addition to 20 μL of 1M potassium phosphate buffer 
solution and 20 μL of 6.25mg/ml choramine T solution, and incubated on ice for 2 min.  140 
μL of cyanoline blue solution (0.27 % w/v) in pyridine-water (1:5, v/v) was added to the 
microtiter plate followed by 20 min incubation at room temperature.  Following incubation, 
sample absorbance was measured at 620 nm using a microplate reader.  
 
2.5 Statistics 
A two-way (treatment by group) ANOVA with repeated measures for treatment (CON, PLA 
and NIT) was employed to determine the effects of the different dietary interventions on 
plasma and salivary [NO3-] and [NO2-] in the smokers and non-smokers.  Where the analysis 
revealed a significant main or interaction effect, simple follow-up contrasts were employed to 
determine the origin of such effects.  Paired samples t-tests were employed to compare the 
effects of PLA and NIT on blood pressure variables.  Pearson’s product moment correlation 
coefficient was used to assess the relationship between changes in variables across conditions 
in the smokers and non-smokers. All data are presented as mean ± SD unless otherwise 
indicated.  Statistical significance was accepted when P<0.05.   
9 
 
3. RESULTS 
 
The PLA and BR supplements administered in this study were well tolerated by all subjects 
with no negative side effects reported.  Subjects self-reported that they consumed all doses of 
the supplement for each experimental condition and that their diet and physical activity 
patterns were consistent across all the dietary interventions.  Smokers confirmed that their 
smoking habits remained consistent across the experimental testing period and that they 
avoided smoking a cigarette for at least 3 hours before each experimental testing session as 
instructed.  There was a main effect for group on expired [CO] (P<0.01) with smokers 
exhibiting a higher expired [CO] than non-smokers in CON (6 ± 3 ppm vs. 2 ± 1 ppm), PLA 
(6 ± 2 ppm vs. 2 ± 1 ppm) and NIT (6 ± 3 ppm vs. 2 ± 0 ppm; P<0.01 for all comparisons), 
with no differences in expired [CO] between treatments in either the smokers or non-smokers 
(P>0.05 for all comparisons). 
 
3.1 Salivary and plasma [SCN-]  
Salivary [SCN-] was higher in smokers than non-smokers in CON, PLA and NIT (P<0.05 for 
all comparisons; Figure 1).  Salivary [SCN-] was lower in NIT than CON and PLA in both 
smokers and non-smokers (P<0.05 for all comparisons).  Plasma [SCN-] was higher in 
smokers than non-smokers in CON, PLA and NIT (P<0.05 for all comparisons).  There were 
no between-treatment differences in either the smoking or non-smoking groups (P>0.05 for 
all comparisons).       
 
3.2 Salivary and plasma [NO3-] and [NO2-]    
There was a group × treatment interaction effect for salivary [NO3-] (P<0.05).  Further 
analyses revealed that salivary [NO3-] was higher than CON and PLA in NIT in both smokers 
and non-smokers (P<0.01 for all comparisons; Figure 2), with a lower salivary [NO3-] 
observed in smokers compared to non-smokers in NIT (P<0.05).  A negative correlation was 
observed between the salivary [SCN-] in the CON condition and the change in the salivary 
[NO3-] between the CON and NIT conditions in the smokers (r = -0.78, P<0.01; Figure 3)  
There was a main effect for treatment on salivary [NO2-] (P<0.01) with salivary [NO2-] being 
higher than CON and PLA in NIT in both smokers and non-smokers (P<0.01 for all 
comparisons, Figure 2).  However, there were no differences between smokers and non-
smokers in any of the experimental conditions (P>0.05).               
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 There was a group × treatment interaction effect for both plasma [NO3-] and [NO2-] 
(P<0.01).  Plasma [NO3-] and [NO2-] were not different between smokers and non-smokers in 
CON and PLA (P>0.05).  While plasma [NO3-] and [NO2-] were higher than CON and PLA 
with NIT in both smokers and non-smokers (P<0.01), plasma [NO3-] and [NO2-] were lower 
in smokers than non-smokers in NIT (P<0.01, Figure 2).   
 
3.3 Blood pressure    
Systolic, diastolic and mean arterial blood pressures were not different between the smokers 
and non-smokers in the NIT and PLA conditions (P>0.05, Table 1).  Systolic blood pressure 
was lowered in the NIT condition compared to PLA in non-smokers (P<0.05), but not 
smokers (P>0.05; Figure 4).  There were no differences in diastolic blood pressure or mean 
arterial pressure between the smoking and non-smoking groups in the PLA and NIT 
conditions (P>0.05). There was a negative correlation between the change in in plasma [NO2-
] and the change in systolic blood pressure (r = -0.71, P<0.05), but not diastolic (r = -0.17) or 
mean arterial blood pressure (r = -0.36) in the non-smokers between the PLA and NIT trials 
(P>0.05).  There were no correlations between the change in plasma [NO2-] and the changes 
in systolic (r = 0.25) diastolic (r = 0.08) and mean arterial (r = 0.24) blood pressure in the 
smokers between the PLA and NIT trials (P>0.05).    
 
4. DISCUSSION 
 
The important novel findings from this study are that, despite consuming the same absolute 
NO3- dose, the increases in salivary [NO3-], plasma [NO3-] and plasma [NO2-] were 
essentially halved in smokers compared to non-smokers, and blood pressure was only 
improved in non-smokers.  These findings are important because they suggest that cigarette 
smokers may not derive the same vascular benefits, compared to age-, BMI- and activity-
matched non-smoking controls, if they increase dietary NO3- intake.  Therefore, our findings 
might provide novel insights into the potential risk factors that predispose cigarette smokers 
to increased cardiovascular disease morbidity.   
 
In the CON condition, where participants did not receive any dietary supplementation, 
plasma and salivary [SCN-] were 122% and 89% higher in the smokers compared to the non-
smokers.  Plasma and salivary [SCN-] were also higher in the smokers compared to the non-
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smokers after PLA and NIT supplementation.  Several previous studies have reported 
increased plasma and salivary [SCN-] in smokers compared to non-smokers [43,48].   It is 
known that cigarette smoke contains cyanide [38] and that the increase in systemic [SCN-] in 
cigarette smokers is consequent to cyanide detoxification facilitated by the enzymes, 
thiosulfate sulfotransferase (rhodanase) and 3-mercaptopyruvate sulfurtransferase [42].  
Consequently, salivary/plasma [SCN-] has been recommended as an objective marker of 
smoking status [43,49].  However, it has been suggested that expired [CO] might be a more 
sensitive bio-marker of smoking status than salivary/plasma [SCN-] [50-52].  Expired [CO] 
was 200% higher in the smokers compared to the non-smokers in all experimental conditions 
in this study.  Taken together, these findings confirm that the participants in our smoking 
group were indeed active smokers, and that they consistently adhered to the requirement to 
abstain from smoking for 3 h before each testing session.   
 
In line with previous studies, salivary and plasma [NO3-] and [NO2-] were increased 
following dietary NO3- supplementation in this study [47,53].  However, despite oral 
consumption of the same absolute NO3- dose (8.4 mmol), the increase in salivary [NO3-] 
above CON in the smokers (3510 μM) was only 48% of that observed in the non-smokers 
(7289 μM).  These findings are consistent with previous observations of a lower salivary 
NO3- uptake after oral NO3- consumption in smokers compared to non-smoking controls 
[44,45].  This antagonism of salivary NO3- uptake after NO3- supplementation is likely 
mediated by greater plasma and salivary [SCN-] in the smokers since it has been suggested 
that NO3- and SCN- share a common transporter for uptake into the salivary circulation and 
that SCN- has a higher affinity for salivary uptake than NO3- [36].  In support of a 
competitive inhibition of salivary NO3- uptake by SCN-, the change in the salivary [NO3-] 
between the CON and NIT conditions was negatively correlated with the salivary [SCN-] in 
CON in the smokers (figure 3).  Further support for competition between NO3- and SCN- for 
passage into the salivary circulation is evidenced by the lower salivary [SCN-] in NIT 
compared to CON in both the smokers (-33%) and non-smokers (-38%) in this study.  
Collectively, these findings lend support to the notion that NO3- and SCN- share a common 
salivary transporter(s), possibly sialin [54], and that SCN- can competitively inhibit salivary 
NO3- uptake.     
 
Although salivary [NO3-] was lower after NIT in the smokers compared to the non-smokers, 
salivary [NO2-] was not different between smokers and non-smokers after NIT.  These 
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observations are consistent with previous findings of a similar salivary [NO2-] in smokers and 
non-smokers after NO3- ingestion in spite of a lower salivary [NO3-] [44].  It has been 
reported that the Km of the oral bacteria NO3- reductases for NO3- is ~ 1000 µM [55,56].  
Salivary [NO3-] increased to a mean concentration 7450 μM after NIT in the non-smokers 
and a mean value of 3708 μM in the smokers in this study.  Therefore, it is possible that the 
similar salivary [NO2-] after NIT in the smokers and non-smokers might be related to both 
groups obtaining a saturating salivary [NO3-] for the oral NO3- reductases after NIT.  
However, more recent studies have reported that increasing the salivary [NO3-] to a greater 
extent than achieved in the current study (~12-16 mM) can lead to further increases in 
salivary [NO2-] (~2.5 mM vs. ~1.5 mM in the current study), at least in non-smokers [47, 53].  
These results challenge the previously reported Km of the oral bacteria NO3- reductases for 
NO3- [55,56].  Therefore, further research is required to resolve the mechanisms than underlie 
the similar increase in salivary [NO2-] in spite of a lower increase in salivary [NO3-] after 
NO3- supplementation in smokers, and the Km of the oral bacteria NO3- reductases for NO3-.      
 
Circulating plasma [NO3-] and [NO2-] were both increased compared to CON and PLA after 
NIT in non-smokers, as reported elsewhere [9,11-13,24,31,32,33,57].  However, despite 
plasma [NO3-] and [NO2-] also increasing above values observed in the CON condition in the 
smokers, plasma [NO3-] and [NO2-] were only increased to 60% and 39% of the values 
observed in the non-smokers after NIT.  It has been reported that smoking a single cigarette 
transiently lowers plasma [NO3-] and [NO2-] for 60 minutes [58].  However, since our 
participants were asked to abstain from smoking for 3 hours prior to reporting to the 
laboratory, and since the expired [CO] was not different in the smokers across the 
experimental conditions, it is unlikely that the blunted increases in plasma [NO3-] and [NO2-] 
after NIT in the smokers can be ascribed to the acute effects of smoking.  Given that salivary 
NO3- uptake was lower in the smokers, the lower plasma [NO3-] after NIT in this group might 
have been a function of increased NO3- excretion in urine to offset excessive plasma NO3- 
accumulation.  The lower plasma [NO2-] after NIT in the smokers compared to the non-
smokers, in spite of a similar salivary [NO2-], might also be linked to increased NO2- 
excretion.  Alternatively, it is possible that the SCN--catalysed reduction of NO2- to NO in the 
stomach [59] was increased in the smokers, which might have attenuated NO2- uptake into 
the systemic circulation.  In addition, smokers have an elevated myloperoxidase activity in 
neutrophils [60], which has been reported to catalyse NO2- oxidation [61] and might have 
contributed to the lower plasma [NO2-] after NIT in the smokers.  Finally, it has been 
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suggested that cigarette smoking impairs NO generation through eNOS, by lowering eNOS 
expression [62] and/or promoting eNOS uncoupling [63], and that the chemical reduction of 
NO2- can compensate for the perturbed cardiovascular function associated with NOS 
dysfunction [64-66].  Therefore, the lower plasma [NO2-] after NIT in the smokers in this 
study might be reflective of an increased NO2- reduction to NO through xanthine oxidase [67] 
or other NO2- reductases [30] as a compensatory mechanism for a potential shortfall in 
eNOS-derived NO. 
 
Compared to PLA, systolic blood pressure was significantly lowered by 3 mmHg after NIT in 
the normotensive non-smokers who participated in this study.  These findings are consistent 
with several [9,11-15], but not all [e.g., 68], previous reports of lower blood pressure after 
NIT in normotensive non-smoking participants.  In addition, we observed a significant 
negative correlation between the change in plasma [NO2-] and the change in systolic blood 
pressure between the PLA and NIT conditions in the non-smokers, consistent with the effects 
of NO2- [28,29] or NO [30, 57] on smooth muscle relaxation, and with previous reports of 
negative correlations between the changes in plasma [NO2-] and blood pressure [57].  
However, while NIT increased plasma [NO2-], and therefore the potential for O2-independent 
NO generation [30], it is unclear whether the lowering of blood pressure is mediated through 
classical NO-cyclic guanosine monophosphate (cGMP) signalling.  NO3- supplementation has 
been reported to increase plasma [NO2-] and lower blood pressure in association with 
increased plasma [cGMP] in some studies [57], but recent evidence also suggests that the 
lowering of blood pressure following NO3- supplementation might be mediated by 
modulating renal physiology [69].  Therefore, the mechanisms that underlie the lowering of 
blood pressure after short-term NO3- supplementation requires further investigation.          
 
In the smokers, blood pressure was not different between the NIT and PLA trials.  It is 
important to note that the mean increase in plasma [NO2-] after ingesting 8.4 mmol of NO3--
rich beetroot juice was 218 nM in the smokers, which was only 39% of the mean plasma 
[NO2-] observed in the non-smokers after NIT, and is comparable with the mean 220 nM 
increase in plasma [NO2-] after ingesting only 4.2 mmol of NO3--rich beetroot juice in our 
previous dose-response study [13].  While the lack of a significant blood pressure reduction 
might be ascribed, at least in part, to a lower plasma [NO2-] in smokers after NIT, systolic 
blood pressure but not diastolic or mean arterial blood pressures, was significantly lower after 
the ingestion of 4.2 mmol of NO3--rich beetroot juice in our previous dose-response study 
14 
 
[13].  Smokers have been reported to exhibit increased plasma nitrotyrosine levels [70], 
potentially indicative of increased scavenging of NO by superoxide [71].  This suggests that 
the bioavailability of NO2--derived NO, and the accompanying lowering of blood pressure, 
might be compromised in smokers at a given NO3- dose.  Moreover, cigarette smoking is 
associated with heightened inflammatory, oxidative and nitrative stress, which contributes to 
vascular remodelling and biochemical dysfunction [72-74].  These negative effects on the 
vasculature might lower the responsiveness of the blood vessels to dilate at a given plasma 
[NO2-] which could account for our findings of improved blood pressure in non-smokers, but 
not smokers, after short-term dietary NO3- supplementation.    
         
It is well documented that hypertension [77] is an independent predictor of cardiovascular 
disease morbidity and mortality.  The magnitude of systolic blood pressure reductions in this 
study would be expected to lower the incidence of stroke and ischemic heart disease [79].  
These observations suggest that the blood pressure reductions after short-term NIT in non-
smokers might be expected to confer a lower risk for cardiovascular disease morbidity and 
adverse cardiovascular events.  Conversely, and despite ingesting the same absolute NO3- 
dose as the non-smokers, blood pressure was not lowered after NIT in the smokers.  By 
suggesting that cigarette smokers might not improve blood pressure if they increase dietary 
NO3- intake, our data provide potential novel insights into the risk factors for cardiovascular 
disease morbidity in cigarette smokers.  Since the attenuated effects of NIT on blood pressure 
appear to be linked, at least in part, to a SCN--mediated perturbation to dietary NO3- 
metabolism, and since circulating SCN- is increased dose-dependently with smoking status 
[43], it is possible that the antagonistic effects of SCN- on dietary NO3- metabolism and its 
associated physiological responses are even greater in individuals with a higher number of 
pack years than the light smokers (7 ± 6 pack years) who participated in this study.  
Similarly, since we instructed smokers to abstain from cigarette smoking for 3 hours prior to 
reporting to the laboratory, the potential for NO3- supplementation to offset the transient 
increase in blood pressure [80] and lowering of plasma [NO2-] [58] was not explored in this 
study and could represent a positive effect of dietary NO3- supplementation in cigarette 
smokers.  It is also important to stress that, although the findings of this study suggest that 
cigarette smokers might not improve blood pressure if they increase dietary NO3- intake, 
increased NO3--rich vegetable consumption will provide other nutrients that can benefit 
human health [2,3].  Moreover, it is possible that increased NO3- intake might have improved 
aspects of health in smokers that were not investigated in this study or that cigarette smokers 
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might need to consume a greater NO3- dose to lower blood pressure compared to their non-
smoking counterparts.  Therefore, further research is required to assess the health outcomes 
and underlying mechanisms of compromised dietary NO3- metabolism in cigarette smokers.   
 
5. CONCLUSION 
 
In conclusion, salivary [NO3-], plasma [NO3-] and plasma [NO2-] were lower by ~ 50% in 
cigarette smokers compared to non-smoking controls after ingesting the same absolute NO3- 
dose.  This perturbation to dietary NO3- metabolism in cigarette smokers abolished the 
improvement in blood pressure that was observed in the non-smokers after NO3- 
supplementation.  These findings suggest that cigarette smokers are less likely to improve 
blood pressure if they were to increase dietary NO3- intake.  These observations might 
provide important novel insights into the mechanisms by which cigarette smoking 
predisposes to increased cardiovascular disease morbidity and mortality.      
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Figure Legends 
 
Figure 1:  Mean salivary (upper panel) and plasma (lower panel) thiocyanate concentrations 
([SCN-]) following no dietary supplementation (CON), supplementation with nitrate-depleted 
beetroot juice (PLA) and supplementation with nitrate-rich beetroot juice (NIT) in smokers 
and non-smokers.  The filled bars represent the group mean ± SEM responses in the CON, 
PLA and NIT conditions in non-smokers, while the open bars represent the group mean ± 
SEM responses in the CON, PLA and NIT conditions in smokers. # indicates significantly 
different from the smokers in the same experimental * indicates significantly different from 
responses in CON and PLA.  Note condition. the higher mean salivary and plasma [SCN-] in 
smokers in all experimental conditions and the lower salivary [SCN-] in NIT compared to 
CON and PLA in both smokers and no-smokers.     
 
Figure 2:  Mean salivary and plasma nitrate ([NO3-]) and nitrite ([NO2-]) concentrations 
following no dietary supplementation (CON), supplementation with nitrate-depleted beetroot 
juice (PLA) and supplementation with nitrate-rich beetroot juice (NIT) in smokers and non-
smokers.  Salivary [NO3-] responses are shown in the upper left panel, salivary [NO2-] 
responses are shown in the upper right panel, plasma [NO3-] responses are shown in the 
lower left panel and salivary [NO2-] responses are shown in the lower right panel.  The filled 
bars represent the group mean ± SEM responses in the CON, PLA and NIT conditions in 
non-smokers, while the open bars represent the group mean ± SEM responses in the CON, 
PLA and NIT conditions in smokers.  # indicates significantly different from the smokers in 
the same experimental condition. * indicates significantly different from responses in CON 
and PLA.  Note the significant increases in mean salivary and plasma [NO3-] and [NO2-] with 
NIT supplementation in both smokers and non-smokers and that the increases in the salivary 
[NO3-] and plasma [NO3-] and [NO2-] were lower following oral consumption of the same 
NIT dose in smokers compared to non-smokers.       
 
Figure 3:  The relationship between salivary thiocyanate concentration ([SCN-]) with no 
supplementation (CON) and the change (Δ) in salivary nitrate concentration ([NO3
-]) between 
the CON and NIT conditions in smokers.  Note that the salivary [SCN-] in CON was 
negatively correlated with Δ CON-NIT salivary [NO3-].     
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Figure 4:  The individual changes in systolic, diastolic and mean arterial blood pressures 
following supplementation with nitrate-depleted beetroot juice (PLA) and supplementation 
with nitrate-rich beetroot juice (NIT) in smokers and non-smokers. * indicates significantly 
different from responses in PLA. 
Table 1. Resting supine blood pressure measures following nitrate-depleted beetroot 
juice supplementation (PLA) and nitrate-rich beetroot juice supplementation (NIT) in 
smokers and non-smokers. 
 
 Smokers 
 PLA NIT 
Systolic blood pressure (mmHg) 109 ± 8 110 ± 7 
Diastolic blood pressure (mmHg)  59 ± 6 59 ± 5 
Mean arterial pressure (mmHg) 79 ± 5 79 ± 4 
   
 Non-smokers 
 PLA NIT 
Systolic blood pressure (mmHg) 103 ± 8 100 ± 10* 
Diastolic blood pressure (mmHg)  59 ± 4 58 ± 8 
Mean arterial pressure (mmHg) 76 ± 6 74 ± 9 
Values are presented as the mean ± SD. * = significantly different from PLA (P<0.05).  
 




